Modest decline in late mortality following Hodgkin's disease in the southeastern Netherlands since 1972

Annals of Hematology

Volumn 76, Issue 5, 1998, Pages 205-209

  Van Spronsen, D J ^a,d   Post, P N ^c   Crommelin, M A ^a,b   Breed, W P M ^a,b   Coebergh, J W W ^b,c  

^a CATHARINA HOSPITAL   (Netherlands)

^b Municipal Health Services GGD   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cause of death; Hodgkin's disease; Mortality; Population based

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; HISTOLOGY; HODGKIN DISEASE; HUMAN; IATROGENIC DISEASE; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MEDICAL RECORD; NETHERLANDS; PRIORITY JOURNAL; SECOND CANCER;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; INFECTION; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NETHERLANDS; PREVALENCE; PULMONARY FIBROSIS; RADIOTHERAPY; SURVIVAL RATE;

EID: 0031812727     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050390     Document Type: Article

References (23)

1. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaloy S, Host H (1993) Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 11:255-261
2. Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G (1990) Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8:1148-1154
3. Biti G, Cellai E, Magrini SM, Papi MG, Ponticelli P, Boddi V (1994) Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 29:25-31
4. Boivin JF, Hutchison GB, Lubin JH, Mauch P (1992) Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241-1247
5. Bookman MA, Longo DA, Young RC (1988) Late complications of curative treatment in Hodgkin's disease. JAMA 260:680-683
6. Greenwood M (1968) Reports on public health and medical subjects, no. 33, appendix 1:the "errors of sampling" of the survivorship tables. Her Majesty's Stationary Office. London
7. Hakulinen T, Abeywickrama KH (1985) A computer package for relative survival analysis. Comp Prog Biomed 19:197-207
8. Hancock SI, Cox RS, McDougaall IR (1991) Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 325:599-605
9. Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949-1955
10. Henry-Amar M, Hayat M, Meerwaldt JH, et al (1990) Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. Int J Radiat Oncol Biol Phys 19:1155-1157
11. Hoppe RT (1997) Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 8:S115-S118
12. Kaldor JM, Day NE, Clarke EA, et al (1990) Leukemia following Hodgkin's disease. N Engl J Med 322:7-13
13. Kaldor JM, Day NE, Bell J, et al (1992) Lung cancer following Hodgkin's disease: a case control study. Int J Cancer 52:677-681
14. Pedersen-Bjergaard J, Olesen Larsen S, Struck J, et al (1987) Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Lancet 2:83-88
15. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA (1992) Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 304:1137-1143
16. Swerdlow AJ, Barber JA, Horwich A Cunningham D, Milan S, Omar RZ (1997) Second malignanciy in patients with Hodgkin's disease treated in the Royal Marsden Hospital. Br J Cancer 75:116-123
17. Tucker MA, Coleman CN, Cox RS, Varghese A Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988:76-81
18. Urba WJ, Longo DL (1992) Hodgkin's disease. N Engl J Med 326:678-687
19. Valagussa P, Santoro A, Fossati-Bellani F, et al (1986) Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837
20. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EHM, van Heerde P, Somers R (1994) Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 12:312-325
21. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EHM, Pinedo HM, van Heerde P, Somers R (1994) Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073
22. Van Spronsen DJ, Dijkema IM, Vrints LW, Hofstra G, Crommelin MA, Erdkamp FLG, Coebergh JWW, Breed WPM (1997) Improved survival of Hodgkin patients in the South-east Netherlands since 1972. Eur J Cancer 33:436-441
23. Vaughan Hudson B, Vaughan Hudson G, Linch DC, Anderson L (1994) Late mortality in young BNLI patients cured of Hodgkin's disease. Ann Oncol 5:65-66